ALFA Finder| Execution period | 60 Months |
|---|
NSE filing, NSE: IPCALAB. Summary written from the filing by ALFA Finder's alert engine.
Ipca Laboratories Ltd: key numbers
- Share price
- ₹1,938.40
- Market cap
- ₹49,178 Cr
- Revenue (annual)
- ₹9,646 Cr
- Net profit (annual)
- ₹1,141 Cr
- P/E (TTM)
- 35.1×Sector 43.8×
- Promoter holding
- 44.72%+0.00% QoQ
- FII holding
- 11.53%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Ipca Laboratories Ltd
All →Ipca Laboratories Earnings Call Transcript: Key Takeaways
Consolidated sales rose about 14% to ₹2,910 Cr and EBITDA margin reached 22.97%, inside the 22-23% guided band. Management reiterated FY27 guidance without a raise.
Ipca Laboratories Q2 FY27 Results: Net Profit ₹389.3 Cr, Up 38.8% YoY
Ipca Laboratories Ltd reported revenue from operations of ₹2,910 Cr (+13.8% YoY) and net profit of ₹389.3 Cr (+38.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹389.3 Cr · +38.8% YoY
Ipca Laboratories Board Meeting Date
Ipca Laboratories board meeting set for 5 November 2026 to approve Q2 and H1 FY27 unaudited results. Insider trading window remains closed until two days after declaration.
Ipca Laboratories Other Announcement
Ipca Laboratories Ltd submitted its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with Regulation 31(1)(b) of the SEBI Listing Regulations.
Ipca Laboratories Earnings Call Transcript: Key Takeaways
Ipca reported strong Q1FY27 with 21% consolidated revenue growth and EBITDA margins expanding 449bps to 22.88%. Management raised full-year growth and margin guidance based on robust generic and domestic performance.
- Call
- Guides 16% growth
Ipca Laboratories Annual General Meeting
Ipca Laboratories held its 76th Annual General Meeting, covering the adoption of financial statements, dividend declaration, and director appointments. No voting results were included.
Other management change announcements
All →Edelweiss Financial Services Management Change
Promoter director Venkatachalam Ramaswamy resigned as Non-Executive Director and Vice Chairman effective November 11, 2026. He also sought reclassification from promoter to public category, pending approvals.
Abans Financial Services Management Change
Abans Financial Services' Chief Executive Officer Chintan Mehta resigned with immediate effect. Mayank Mundhra was appointed Whole-Time Director from November 11, 2026, subject to shareholder approval.
Ortin Global Management Change
Ortin Global's auditor M/s. Mathesh & Ramana resigned effective 12 Nov 2026, citing other professional commitments. S. D. Mehta and Co. was appointed as replacement.
Tierra Agrotech Management Change
Tierra Agrotech appointed Sridevi Dasari as Executive Director for 60 months, effective 16 November 2026. She is Group Company Secretary and Legal Head of CCL Products (India).
- Execution
- 60 months
National Peroxide Management Change
National Peroxide Limited appointed Mr. Amit Shah as General Manager – Sales & Marketing, effective 11 November 2026, as a senior management personnel change. The appointment was approved at a board meeting held the same day.
Naperol Investments Management Change
Naperol Investments appointed Mr. Vinay Divakar Jayade as Non-Executive Non-Independent Director and Ms. Jinal Shah as Company Secretary, both effective 11 November 2026. Board-approved appointments with no financial value disclosed.
- Execution
- 3 months (Mr. Jayade's term of appointment)